Note 16 - Subsequent Events (Details Textual) - Subsequent Event [Member] - USD ($) $ in Millions |
Apr. 30, 2025 |
Apr. 28, 2025 |
---|---|---|
Former Employee [Member] | ||
Stock Issued During Period, Shares, New Issues (in shares) | 21,000 | |
Inducement Agreement [Member] | ||
Stock Issued During Period, Shares, New Issues (in shares) | 340,000 | |
Evoke Neuroscience, Inc. [Member] | ||
Business Combination, Consideration Transferred | $ 6.0 | |
Payments to Acquire Businesses, Gross | $ 3.0 | |
Business Combination, Consideration Transferred, Equity Interest, Share Issued, Number of Shares (in shares) | 857,149 | |
Business Combination, Consideration Transferred, Equity Interest | $ 3.0 | |
Evoke Neuroscience, Inc. [Member] | Earnout Targets [Member] | ||
Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount | $ 0.5 |
X | ||||||||||
- Definition Number of shares of equity interest issued or issuable by acquirer as part of consideration transferred in business combination. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition Maximum amount of estimate for undiscounted range of outcomes in contingent consideration arrangement in business combination. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|